Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Incyte (INCY)
:INCY
Holding INCY?
Track your performance easily
INCY Stock Chart & Stats
Day’s Range― - ―
52-Week Range$50.35 - $83.95
Previous CloseN/A
Volume384.35K
Average Volume (3M)1.75M
Market Cap
$13.59B
Enterprise Value$11.21B
Total Cash (Recent Filing)$808.55M
Total Debt (Recent Filing)$651.48M
Price to Earnings (P/E)512.5
Beta0.89
Next Earnings
Feb 13, 2025EPS Estimate
1.51Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.14
Shares Outstanding192,650,250
10 Day Avg. Volume1,441,076
30 Day Avg. Volume1,750,679
Standard Deviation0.08
R-Squared0.20
Alpha-0.00872
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)3.33
Price to Cash Flow (P/CF)10.90
P/FCF Ratio11.60
Enterprise Value/Market Cap0.82
Enterprise Value/Revenue2.75
Enterprise Value/Gross Profit3.26
Enterprise Value/Ebitda30.93
Forecast
1Y Price Target
$77.56Price Target Upside7.17% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering18
Incyte News
PremiumCompany Announcements
Incyte Announces Retirement of Executive VP Barry Flannelly
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessThe tafa triplet therapy demonstrated a 59% reduction in the risk of progression in the inMIND Phase 3 trial.
Market OpportunityPovorcitinib could generate approximately $2 billion in peak revenues in hidradenitis suppurativa, indicating a significant market opportunity.
Product LaunchesThree potential launches in 2H25 are expected to contribute up to ~$1B in revenues.
Bears Say
Intellectual Property ConcernsDespite positive expectations for povorcitinib sales, there is concern over the near-term Jakafi intellectual property expiration, requiring more pipeline successes for improvement.
Pipeline ChallengesRecent discontinuations and missteps give pause despite some bright spots in Incyte's pipeline.
Revenue And Growth IssuesOpzelura revenue will be challenged by lower tube usage, and assets like povorcitinib and axatilimab show promise but will not address the Jakafi LOE.
---
Ownership Overview
15.68% Insiders
22.48% Mutual Funds
0.30% Other Institutional Investors
36.46% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
INCY FAQ
What was Incyte’s price range in the past 12 months?
Incyte lowest stock price was $50.35 and its highest was $83.95 in the past 12 months.
What is Incyte’s market cap?
Incyte’s market cap is $13.59B.
When is Incyte’s upcoming earnings report date?
Incyte’s upcoming earnings report date is Feb 13, 2025 which is in 29 days.
How were Incyte’s earnings last quarter?
Incyte released its earnings results on Oct 29, 2024. The company reported $1.07 earnings per share for the quarter, beating the consensus estimate of $1.051 by $0.019.
Is Incyte overvalued?
According to Wall Street analysts Incyte’s price is currently Undervalued.
Does Incyte pay dividends?
Incyte does not currently pay dividends.
What is Incyte’s EPS estimate?
Incyte’s EPS estimate is 1.51.
How many shares outstanding does Incyte have?
Incyte has 192,650,250 shares outstanding.
What happened to Incyte’s price movement after its last earnings report?
Incyte reported an EPS of $1.07 in its last earnings report, beating expectations of $1.051. Following the earnings report the stock price went up 12.041%.
Which hedge fund is a major shareholder of Incyte?
Currently, no hedge funds are holding shares in INCY
---
Incyte Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$77.56 (7.17% Upside)
$77.56 (7.17% Upside)
Blogger Sentiment
Bullish
INCY Sentiment 70%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 410.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $839.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.3%
Last 30 Days ▼ 4.8%
Last 30 Days ▼ 4.8%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
15.34%
12-Months-Change
Fundamentals
Return on Equity
0.80%
Trailing 12-Months
Asset Growth
-21.54%
Trailing 12-Months
Company Description
Incyte
Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development and commercialization of proprietary therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late stage development, and commercialized products such as JAKAFI (ruxolitinib), and ICLUSIG (ponatinib). The company was founded by Roy A. Whitfield in April 1991 and is headquartered in Wilmington, DE.
---
INCY Company Deck
---
INCY Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented a strong performance by Incyte, with significant revenue growth and key product approvals. The pipeline is progressing well with several promising developments. However, there were notable increases in R&D and SG&A expenses. Overall, the positive aspects outweigh the negatives, indicating a strong quarter for Incyte.Read More>---
INCY Revenue Breakdown
85.65% Product revenues, net
14.16% Product royalty revenues
0.19% Milestone and contract revenues
---
INCY Stock 12 Month Forecast
Average Price Target
$77.56
▲(7.17% Upside)
Technical Analysis
Alnylam Pharma
―
BioMarin Pharmaceutical
―
Exelixis
―
Vertex Pharmaceuticals
―
Regeneron
―
Best Analysts Covering INCY
1 Year
1 Year Success Rate
26/31 ratings generated profit
1 Year Average Return
+13.26%
reiterated a buy rating last month
Copying Marc Frahm's trades and holding each position for 1 Year would result in 83.87% of your transactions generating a profit, with an average return of +13.26% per trade.
---